Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes, which is present top line interim results of a Phase 3 clinical trial.
Lead Product(s): EuCorVac-19
Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: EuBiologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2023